Even though the inflammasome seems to be an optimal target to treat autoimmune diseases and reduce associated CV, drugs that target the NLRP3 inflammatory pathway can have serious adverse effects, such as an increased risk of infection (anakinra, canakinumab and tofacitinib) [83]. Here, NLRP3 is linked to autoimmune disease.